Serum Concentrations of Cholinesterase Inhibitors in Patients With Alzheimer's Dementia Are Frequently Below the Recommended Levels.
Alzheimer's dementia
Alzheimer's disease
CYP2D6 polymorphism
cholinesterase inhibitors
gene dose
serum concentration
therapeutic drug monitoring
treatment efficacy
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
09
2019
accepted:
27
04
2020
entrez:
9
6
2020
pubmed:
9
6
2020
medline:
9
6
2020
Statut:
epublish
Résumé
Acetylcholinesterase inhibitors (AChE-I) are recommended for the treatment of cognitive symptoms but also of behavioral and psychological symptoms in dementia. They are widely used not only in Alzheimer's disease, but also in other forms of dementia. Efficacy of treatment might depend on serum concentration of the respective AChE-I. In patients with mild to moderate Alzheimer's dementia, we measured serum concentrations of hepatically metabolized donepezil and renally excreted rivastigmine and investigated possible modifiers. Additionally, we looked at correlations between serum concentrations and efficacy for both drugs. Serum concentrations of donepezil and rivastigmine were measured by liquid chromatography - tandem mass spectrometry (LC-MS/MS). Real-time quantitative polymerase chain reaction (PCR). Allele specific PCR were performed to determine CYP2D6 genotype and gene dose. Clinical efficacy was assessed by changes of the subtest wordlist delayed recall of the Consortium to Establish a Registry for Alzheimer's Disease-Neuropsychological Assessment Battery (CERAD-NAB). Sixty-seven patients treated with a stable dosage of donepezil 10 mg (n=41) or rivastigmine 9.5 mg (n=26) were included. Mean serum concentration of donepezil and rivastigmine were 41.2 and 6.5 ng/ml, respectively. Serum concentrations were below the recommended range in 73% of the subjects in the donepezil group and in 65% of the participants in the rivastigmine group. When applying a dose-related reference, ranges 63% of patients in the donepezil group and 32% in the rivastigmine group had concentrations below the expected range. Gene dose, sex, and duration of treatment significantly predicted donepezil serum concentration (p=0.046, p=0.001, p=0.030 respectively). Only for rivastigmine did the serum concentration significantly contribute to the regression model predicting changes on the subtest word list delayed recall (β=0.472; p=0.019). Serum concentrations of about two thirds of the patients were below the recommended range. When not looking at absolute values but at the dose-related reference ranges, these numbers improved but still 32%, respectively 63% of patients had low serum concentrations. High serum concentrations of rivastigmine predicted clinical response to cognition. Therapeutic drug monitoring might help to identify the cause of poor clinical response to cognition and behavioral and psychological symptoms in patients with AChE-I treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Acetylcholinesterase inhibitors (AChE-I) are recommended for the treatment of cognitive symptoms but also of behavioral and psychological symptoms in dementia. They are widely used not only in Alzheimer's disease, but also in other forms of dementia. Efficacy of treatment might depend on serum concentration of the respective AChE-I.
OBJECTIVE
OBJECTIVE
In patients with mild to moderate Alzheimer's dementia, we measured serum concentrations of hepatically metabolized donepezil and renally excreted rivastigmine and investigated possible modifiers. Additionally, we looked at correlations between serum concentrations and efficacy for both drugs.
METHODS
METHODS
Serum concentrations of donepezil and rivastigmine were measured by liquid chromatography - tandem mass spectrometry (LC-MS/MS). Real-time quantitative polymerase chain reaction (PCR). Allele specific PCR were performed to determine CYP2D6 genotype and gene dose. Clinical efficacy was assessed by changes of the subtest wordlist delayed recall of the Consortium to Establish a Registry for Alzheimer's Disease-Neuropsychological Assessment Battery (CERAD-NAB).
RESULTS
RESULTS
Sixty-seven patients treated with a stable dosage of donepezil 10 mg (n=41) or rivastigmine 9.5 mg (n=26) were included. Mean serum concentration of donepezil and rivastigmine were 41.2 and 6.5 ng/ml, respectively. Serum concentrations were below the recommended range in 73% of the subjects in the donepezil group and in 65% of the participants in the rivastigmine group. When applying a dose-related reference, ranges 63% of patients in the donepezil group and 32% in the rivastigmine group had concentrations below the expected range. Gene dose, sex, and duration of treatment significantly predicted donepezil serum concentration (p=0.046, p=0.001, p=0.030 respectively). Only for rivastigmine did the serum concentration significantly contribute to the regression model predicting changes on the subtest word list delayed recall (β=0.472; p=0.019).
CONCLUSIONS
CONCLUSIONS
Serum concentrations of about two thirds of the patients were below the recommended range. When not looking at absolute values but at the dose-related reference ranges, these numbers improved but still 32%, respectively 63% of patients had low serum concentrations. High serum concentrations of rivastigmine predicted clinical response to cognition. Therapeutic drug monitoring might help to identify the cause of poor clinical response to cognition and behavioral and psychological symptoms in patients with AChE-I treatment.
Identifiants
pubmed: 32508640
doi: 10.3389/fphar.2020.00691
pmc: PMC7253642
doi:
Types de publication
Journal Article
Langues
eng
Pagination
691Informations de copyright
Copyright © 2020 Ortner, Stange, Schneider, Schroeder, Buerger, Müller, Dorn, Goldhardt, Diehl-Schmid, Förstl, Steimer and Grimmer.
Références
Int J Geriatr Psychiatry. 2008 Feb;23(2):170-7
pubmed: 17607801
Pharmacopsychiatry. 2018 Jan;51(1-02):e1
pubmed: 29390205
Neurology. 1994 Dec;44(12):2308-14
pubmed: 7991117
Pharmacogenet Genomics. 2006 Nov;16(11):771-4
pubmed: 17047484
J Clin Psychopharmacol. 2013 Jun;33(3):351-5
pubmed: 23609381
Aust Fam Physician. 2016 Dec;45(12):884-889
pubmed: 27903038
J Alzheimers Dis. 2016 Nov 19;55(2):539-549
pubmed: 27716659
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
J Neural Transm (Vienna). 2006 Nov;113(11):1791-801
pubmed: 16868793
J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jan 15;881-882:1-11
pubmed: 22204871
Neurology. 1989 Sep;39(9):1159-65
pubmed: 2771064
Ther Drug Monit. 2004 Aug;26(4):459-61
pubmed: 15257079
Epidemiol Psychiatr Sci. 2018 Jun;27(3):278-287
pubmed: 28065176
BMC Geriatr. 2018 Oct 11;18(1):239
pubmed: 30305048
J Alzheimers Dis. 2015;46(3):687-93
pubmed: 26402513
Eur J Clin Pharmacol. 2006 Sep;62(9):721-6
pubmed: 16845507
Eur J Clin Pharmacol. 2016 Jun;72(6):711-7
pubmed: 26952092
Cochrane Database Syst Rev. 2012 Mar 14;(3):CD006504
pubmed: 22419314
Arch Neurol. 1991 Mar;48(3):278-81
pubmed: 2001185
J Neurol Neurosurg Psychiatry. 2005 Dec;76 Suppl 5:v2-7
pubmed: 16291918
Pharmacogenetics. 2003 Apr;13(4):231-9
pubmed: 12668920
J Alzheimers Dis. 2014;41(2):615-31
pubmed: 24662102
Br J Clin Pharmacol. 2014 Jul;78(1):135-44
pubmed: 24433464
Curr Alzheimer Res. 2009 Feb;6(1):4-14
pubmed: 19199870
Neurology. 2001 May 8;56(9):1154-66
pubmed: 11342679
J Neurol. 2019 Oct;266(10):2363-2375
pubmed: 30666436
Clin Ther. 2010 Jul;32(7):1234-51
pubmed: 20678673
Biol Psychiatry. 2015 Apr 15;77(8):704-10
pubmed: 24613195
Annu Rev Pharmacol Toxicol. 1997;37:269-96
pubmed: 9131254
Curr Alzheimer Res. 2010 Feb;7(1):67-73
pubmed: 20205672
Psychogeriatrics. 2016 May;16(3):202-8
pubmed: 26179411
Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593
pubmed: 16437532
Pharmacopsychiatry. 2011 Sep;44(6):195-235
pubmed: 21969060
JAMA. 2002 Sep 25;288(12):1475-83
pubmed: 12243634
Can J Neurol Sci. 2012 Nov;39(6 Suppl 5):S1-8
pubmed: 23073396
JAMA. 2013 Dec 25;310(24):2611-2
pubmed: 24264605
Clin Chem. 2004 Sep;50(9):1623-33
pubmed: 15205367
J Alzheimers Dis. 2012;31(4):857-64
pubmed: 22751168
Cochrane Database Syst Rev. 2015 Mar 03;(3):CD009444
pubmed: 25734590
Clin Pharmacol Ther. 2013 May;93(5):402-8
pubmed: 23486447
Pharmacogenet Genomics. 2011 Apr;21(4):225-30
pubmed: 20859244
J Neurol Sci. 2014 Aug 15;343(1-2):15-22
pubmed: 24909950
Arch Intern Med. 1998 May 11;158(9):1021-31
pubmed: 9588436
Kaohsiung J Med Sci. 2017 Jun;33(6):277-283
pubmed: 28601231
Ther Drug Monit. 2015 Jun;37(3):353-61
pubmed: 25384119
Clin Pharmacol Ther. 2004 Aug;76(2):128-38
pubmed: 15289790
Psychogeriatrics. 2017 Mar;17(2):103-107
pubmed: 27411501
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
J Neurol Sci. 2016 Jul 15;366:184-190
pubmed: 27288803
Dtsch Arztebl Int. 2017 Jun 30;114(26):447-454
pubmed: 28705297
Alzheimers Dement. 2011 Nov;7(6):567-73
pubmed: 22055973
Dement Geriatr Cogn Disord. 2014;37(1-2):58-70
pubmed: 24107805
Am J Hum Genet. 1997 Feb;60(2):284-95
pubmed: 9012401
Cochrane Database Syst Rev. 2015 Sep 22;9:CD001191
pubmed: 26393402
J Alzheimers Dis. 2014;39(2):423-40
pubmed: 24217282